

CLEAN VERSION OF AMENDMENT

In the Claims:

Please amend Claims 15, 19 and 33 as follows:

Sub D/E1
~~18~~ 15. (Once amended) A method for inhibiting angiogenesis in a human or animal comprising administering to the human or animal a composition comprising an antiinflammatory compound and an angiogenesis inhibiting compound comprising thalidomide or an analogue, hydrolysis product, or metabolite thereof with the proviso that when the angiogenesis is associated with rheumatoid arthritis, the angiogenesis inhibiting compound is not thalidomide.

D2 E1
~~20~~ 19. (Once Amended) A method for treating an angiogenesis dependent disease in a human or animal having such a disease comprising administering to the human or animal a composition comprising an angiogenesis inhibiting compound and an anti-inflammatory compound, wherein the angiogenesis inhibiting compound is thalidomide or analogues, hydrolysis products, or metabolites thereof with the proviso that the angiogenesis inhibiting compound is not thalidomide when the angiogenesis dependent disease is rheumatoid arthritis.

D3
~~11~~ 33. (Once amended) The composition of Claim ~~22~~ ¹⁰ wherein the composition comprises a formulation suitable for oral, rectal, ophthalmic, nasal, topical, vaginal, or parenteral administration.

Version With Markings to Show Changes Made Under 37 C.F.R. 1.121(c)(1)(ii)

Please amend the claims by deleting the bracketed word(s) and inserting the underlined word(s) as indicated.

15. (Once amended) A method for inhibiting angiogenesis in a human or animal comprising administering to the human or animal a composition comprising [an angiogenesis inhibiting compound and] an antiinflammatory compound and an angiogenesis inhibiting compound comprising thalidomide or an analogue, hydrolysis product, or metabolite thereof with the proviso that when the angiogenesis is associated with rheumatoid arthritis, the angiogenesis inhibiting compound is not thalidomide.

19. (Once Amended) A method for treating an angiogenesis dependent disease in a human or animal having such a disease comprising administering to the human or animal a composition comprising an angiogenesis inhibiting compound and an anti-inflammatory compound, wherein the angiogenesis inhibiting compound is thalidomide or analogues, hydrolysis products, or metabolites thereof with the proviso that the angiogenesis inhibiting compound is not thalidomide when the angiogenesis dependent disease is rheumatoid arthritis.

33. (Once amended) The [method]composition of Claim 22 wherein the composition comprises a formulation suitable for oral, rectal, ophthalmic, nasal, topical, vaginal, or parenteral administration.